Redwood City, CA – May 24, 2011 – Ingenuity® Systems, a leading provider of information and analysis solutions for life science researchers, and Translational Oncology (TRON) at the Medical University of Mainz, today announced the availability of an early version of a Galaxy plugin for IPA® software. The plugin, still in development, will enable researchers to take RNA-Seq and Re-sequencing processed datasets directly from Galaxy into IPA, for more efficient and impactful biological interpretation of the data.
Galaxy is a free and open source web-based platform for performing integrative genomic analysis. Mainz researchers can upload their NGS data into Galaxy for upstream analysis and narrow in on a subset of genes for further investigation in IPA. Once in IPA, researchers can leverage the rich biological context of Ingenuity’s curated content and analytics to understand which key pathways and biological processes those genes are involved in. This approach is imperative to ensure key insights are not missed, and that researchers have more evidence to support critical observations.
“The Galaxy-IPA plug in, built by researchers at TRON, will help researchers spend less time on the manipulations of data, and more time focusing on the important scientific questions,” commented Dr. John Castle, head of Bioinformatics/Genomics at TRON.
“We are very pleased to collaborate with TRON and the University of Mainz to support their research efforts. With the Galaxy plugin for IPA, this team has provided a streamlined workflow to the research community to help NGS researchers get to powerful biological insights, faster,” stated Stuart Tugendreich Ph.D., Director, Product Management New Solutions, Ingenuity Systems.
About Ingenuity® Systems
Ingenuity Systems is a leading provider of information solutions and custom services for life science researchers, computational biologists and bioinformaticists, and life science industry suppliers. For more information visit: www.ingenuity.com
About the Center for Translational Oncology and Immunology (TRON)
Translational Oncology (TRON) at the Medical University of Mainz was founded in February 2010 as a trans-disciplinary not-for-profit research organization dedicated to innovation transfer. Its founding shareholders include the state of Rhineland Palatinate, the Johannes Gutenberg University, and the University Medical Center Mainz. Under the direction of Professor Dr Ugur Sahin, TRON’s mission is to accelerate medical and scientific discoveries from cutting edge biomarker and drug research to clinical innovation for the diagnosis and treatment of patients.